Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Susan C. Guba
Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-Beta Receptor I, in Combination With Standard Temozolomide-Based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
Investigational New Drugs
Oncology
Pharmacology
Related publications
A Phase 1b Study of Transforming Growth Factor-Beta Receptor I Inhibitor Galunisertib in Combination With Sorafenib in Japanese Patients With Unresectable Hepatocellular Carcinoma
Investigational New Drugs
Oncology
Pharmacology
Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients With Refractory Multiple Myeloma
Clinical Cancer Research
Cancer Research
Oncology
Clinical Phase I Study With an Insulin-Like Growth Factor-1 Receptor Inhibitor: Experiences in Patients With Squamous Non-Small Cell Lung Carcinoma
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
A Phase I/Ii Study of Lomustine and Temozolomide in Patients With Cerebral Metastases From Malignant Melanoma
British Journal of Cancer
Cancer Research
Oncology
Phase I Study of SU5416, a Small Molecule Inhibitor of the Vascular Endothelial Growth Factor Receptor (VEGFR) in Refractory Pediatric Central Nervous System Tumors
Pediatric Blood and Cancer
Oncology
Child Health
Hematology
Perinatology
Medicine
Pediatrics
Phase I Study of Sunitinib and Irinotecan for Patients With Recurrent Malignant Glioma
Journal of Neuro-Oncology
Cancer Research
Oncology
Neurology
Nimotuzumab Prolongs Survival in Patients With Malignant Gliomas: A Phase I/Ii Clinical Study of Concomitant Radiochemotherapy With or Without Nimotuzumab
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Phase I Study of Temozolomide in Paediatric Patients With Advanced Cancer
British Journal of Cancer
Cancer Research
Oncology
The Insulin-Like Growth Factor-I Receptor Inhibitor Figitumumab (CP-751,871) in Combination With Docetaxel in Patients With Advanced Solid Tumours: Results of a Phase Ib Dose-Escalation, Open-Label Study
British Journal of Cancer
Cancer Research
Oncology
